HEALTH PROFESSIONAL · SOURCE READING

Treatment Options for Thymic Carcinoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Treatment options for patients with operable thymic carcinoma include:[2]

Source links and citations

Surgery (en bloc surgical resection) followed by postoperative radiation therapy (PORT) with or without postoperative chemotherapy.

Treatment options for patients with inoperable thymic carcinoma (stage III and stage IV with vena caval obstruction, pleural involvement, pericardial implants, etc.) include:

Chemotherapy.

Chemoradiation therapy.

Chemotherapy followed by surgery (if operable) and radiation therapy.

In most published studies, surgery has been followed by adjuvant radiation therapy.[3,4] A prescriptive dose range has yet to be identified. Most studies use 40 Gy to 70 Gy with a standard fractionation scheme (1.8–2.0 Gy per fraction).

Source links and citations

Evidence (surgery followed by PORT with or without postoperative chemotherapy):

In the largest series reported, data were obtained from a clinical study of 1,320 Japanese patients.[5] Patients with thymic carcinoma were treated with PORT or chemotherapy.

Source links and citations

In the largest series reported, data were obtained from a clinical study of 1,320 Japanese patients.[5] Patients with thymic carcinoma were treated with PORT or chemotherapy.

The 5-year survival rates were 67% for patients treated with total resection, 30% for patients treated with subtotal resection, and 24% for patients whose disease was inoperable.

In the largest series reported, data were obtained from a clinical study of 1,320 Japanese patients.[5] Patients with thymic carcinoma were treated with PORT or chemotherapy.

Adjuvant therapy, including radiation or chemotherapy, did not appear to improve the prognosis in patients with thymic carcinoma.

A multi-institutional retrospective outcome analysis of 186 patients with thymic carcinoma has been reported.[5]

Source links and citations

A multi-institutional retrospective outcome analysis of 186 patients with thymic carcinoma has been reported.[5]

The 5-year survival rates for patients with totally resected thymic carcinoma were 81.5% for patients treated with chemotherapy, 46.6% for patients treated with radiation therapy and chemotherapy, 73.6% for patients treated with radiation therapy alone, and 72.2% for patients who received no adjuvant therapy.

A multi-institutional retrospective outcome analysis of 186 patients with thymic carcinoma has been reported.[5]

This study failed to detect a long-term survival benefit in patients treated with subtotal resection or any statistically significant survival augmentation from the addition of adjuvant radiation to surgical resection.

A multi-institutional retrospective outcome analysis of 186 patients with thymic carcinoma has been reported.[5]

The authors stipulated that no definitive conclusions could be made regarding the role of adjuvant radiation therapy in thymic carcinoma because of sample size limitations.

The results of these studies call into question conventional thinking regarding the efficacy of an aggressive multimodality approach that includes debulking, radiation therapy, and cisplatin-based chemotherapy.[6-8] While other studies support the addition of adjuvant radiation therapy and chemotherapy, optimum treatment regimens are undetermined.

Source links and citations

Chemotherapy is the primary treatment modality for patients with inoperable thymic carcinoma. Most regimens used are similar to those used to treat thymoma and include a platinum compound with or without an anthracycline (PAC [cisplatin, doxorubicin, cyclophosphamide], VIP [etoposide, ifosfamide, and cisplatin], ADOC [doxorubicin, cisplatin, vincristine, cyclophosphamide], cisplatin/etoposide, carboplatin/paclitaxel).[1,9-14]

Source links and citations

Evidence (chemotherapy):

A phase II study evaluated the combination of carboplatin and paclitaxel in 46 patients with unresectable thymic epithelial tumors, including 23 patients with unresectable thymic carcinoma.[14][Level of evidence C3]

Source links and citations

Five of 23 patients with thymic carcinoma had objective responses (21.7%; 90% confidence interval [CI], 9.0%–40.4%).

The median duration of response in patients with thymic carcinoma was 4.5 months (95% CI, 3.4–9.9).

The median progression-free survival for the thymic carcinoma cohort was 5 months (95% CI, 3.0–8.3) and the median overall survival was 20 months (95% CI, 5.0–43.6) after a median follow-up of 59.4 months.

VIP was used in a prospective North American Intergroup trial.[11]

Source links and citations

VIP was used in a prospective North American Intergroup trial.[11]

Two of 8 patients with thymic carcinoma (25%) had a partial response.

VIP was used in a prospective North American Intergroup trial.[11]

The 1-year survival rate for patients with thymic carcinoma was 75% and the 2-year rate was 50%.

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice